Patent · US Active

Fucosylation-deficient cells

US12054751B2 · kind B2 · utility

0Cited by

10References

12Claims

0Family size

Assignee

REGENERON PHARMACEUTICALS, INC. · US

Inventors

Gang Chen · Sammamish, US
Darya Burakov · Tarrytown, US
James P. Fandl · Lagrangeville, US

Key dates

Filing date	Dec 15, 2022
Grant date	Aug 6, 2024
Priority date	—
Expiry date	Dec 15, 2042

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02P20/52
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.